• In late June 2026, LivaNova PLC (NasdaqGS:LIVN) was added to multiple Russell growth and small-cap indexes, including the Russell 2000 Growth-Defensive Index and Russell 3000 Growth Benchmark.
• This broad index inclusion increases the company’s visibility among institutional investors and index trackers, potentially reshaping how LivaNova fits into diversified healthcare and small-cap growth portfolios.
• Next, we’ll examine how LivaNova’s broad Russell index inclusion could influence its existing investment narrative around innovation and growth.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

LivaNova Investment Narrative Recap

To own LivaNova, you need to believe its neuromodulation and cardiopulmonary franchises can support sustained, profitable growth while it manages reimbursement pressure and rising competition. The broad Russell index additions mainly affect trading and visibility rather than the core business, so they do not materially change the near term catalyst around OSA commercialization or the key risk that high R&D and regulatory demands could weigh on margins if approvals or uptake lag.

The recent FDA PMA approval for the aura6000 System for obstructive sleep apnea is the announcement that ties most directly to LivaNova’s current growth story. As investors weigh the impact of index inclusion, many are watching how the OSA rollout and next generation device work, including the planned MRI friendly upgrade, could influence future revenue mix and justify ongoing investment in innovation amid cost and reimbursement pressures.

However, while index inclusion can broaden awareness, investors still need to be mindful of supply chain constraints in cardiopulmonary that could...

LivaNova's narrative projects $1.8 billion revenue and $220.8 million earnings by 2029. This requires 7.4% yearly revenue growth and a $113.7 million earnings increase from $107.1 million today.

Uncover how LivaNova's forecasts yield a $80.60 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already expecting slower revenue growth near 5 percent and only about US$177.7 million in earnings by 2029, so you might see this new index inclusion and supply chain exposure very differently from them and want to compare how your own expectations stack up against those more cautious forecasts.

Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $80.60!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your LivaNova research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Find 41 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.